Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2], Carlos A Lopez, M.D. [3], Shyam Patel [4]; Grammar Reviewer: Natalie Harpenau, B.S.[5]
Other diagnostic studies for acute myeloid leukemia include cytochemistry, flow cytometry, immunohistochemistry, PCR and biopsy.
- This is a test used to differentiate acute myeloid leukemia from acute lymphoblastic leukemia.
- This test uses a stain which reacts to a particular type of leukemic cells.
- The stain causes the granules of most acute myeloid leukemia cells to appear as black spots under the microscope, but it does not cause acute lymphoblastic cells to change colors.
Flow cytometry and immunohistochemistry[edit | edit source]
- In these tests special antibodies are used to detect cancer cells and thus to differentiate acute myeloid leukemia from other leukemias.
- Monoclonal antibody binding to specific antigens, such as CD33 or CD117, are helpful in the diagnosis of acute myeloid leukemia.
- Sufficient sample must be present in order for these tests to be reliable.
- Polymerase chain reaction is a highly sensitive DNA test used to recognize cancer cells in acute myeloid leukemia, especially for detection of minimal residual disease testing or for molecular mutation assessment. Next-generation sequencing is becoming an increasingly important diagnostic test.
- Lumber puncture: Assessment of the cerebrospinal fluid (CSF) can be done via lumbar puncture. This diagnostic study is especially useful for patients with acute myeloid leukemia who have neurologic deficits, as this is concerning for central nervous system involvement. The cell count from the cerebrospinal fluid will show malignant myeloid cells (typically greater than 2 cells per microliter of cerebrospinal fluid). Treatment of cerebrospinal fluid involvement includes methotrexate, hydrocortisone, and cytarabine.[2]
Template:Hematology
Template:WikiDoc Sources